Amitriptyline Has the Most Significant Long-Term Risks; Fluoxetine Has the Least
Among these three antidepressants, amitriptyline carries the greatest long-term risks due to substantial weight gain (1.8 kg documented), the highest burden of anticholinergic and sedative adverse effects, and cardiovascular concerns, while fluoxetine demonstrates the most favorable long-term profile with weight loss during acute treatment (-1.3 kg), weight neutrality in maintenance phase, and fewer serious adverse events. 1
Greatest Long-Term Risks: Amitriptyline
Metabolic and Weight Effects
Amitriptyline is the most potent inducer of weight gain among tricyclic antidepressants 1. The Endocrine Society guidelines specifically identify amitriptyline as causing 1.8 kg weight gain in long-term use, with this weight gain having "deleterious health consequences" that impede patient compliance 1. Within both the SSRI and tricyclic classes, amitriptyline was associated with the greatest risk for weight gain 2.
Adverse Event Burden
Amitriptyline demonstrates significantly more adverse events than either mirtazapine or placebo, particularly:
- Sedative effects (somnolence)
- Anticholinergic side effects (dry mouth, constipation, urinary retention)
- Cardiovascular risks in elderly patients 3
The 2008 American College of Physicians guideline notes that while amitriptyline may have "slightly greater proportion of responders," it is "less well tolerated compared with tricyclic/heterocyclic and SSRI antidepressants" 4.
Long-Term Tolerability
In a 2-year double-blind study, amitriptyline was associated with significantly more adverse events than mirtazapine, with particular concerns about sedative and anticholinergic effects that persist throughout treatment 3. Objectively measured weight gain occurred in 22% of amitriptyline patients versus 13% on mirtazapine 3.
Intermediate Risk: Mirtazapine
Weight and Metabolic Effects
Mirtazapine causes documented weight gain of 1.5 kg in long-term use 1. The FDA label specifically warns about "Increased Appetite and Weight Gain" as a significant adverse reaction 5. In pediatric patients, 49% gained ≥7% body weight (mean 4 kg increase) versus 5.7% on placebo 5.
Sedation and Somnolence
Mirtazapine causes somnolence in 54% of patients versus 18% on placebo 5. This sedation is a primary reason for discontinuation (10.4% discontinued due to somnolence versus 2.2% on placebo) 5.
Cardiovascular and Serious Risks
The FDA label warns about:
- QT prolongation and Torsades de Pointes 5
- Elevated cholesterol and triglycerides 5
- Mean heart rate increase of 3.4 bpm 5
A 2024 real-world Danish study of 93,883 older adults found mirtazapine users had significantly higher risks of discontinuation (IRR=1.55), switching, augmentation, cardiovascular events, and mortality compared to sertraline users 6. Mirtazapine and venlafaxine users had "the most adverse outcomes" 6.
Recent Safety Concerns
A 2025 systematic review concluded there is insufficient evidence to determine mirtazapine's effects on suicides or serious adverse events, with all evidence rated as "very low certainty" 7. The maximum follow-up in trials was only 12 weeks 7.
Least Long-Term Risks: Fluoxetine
Weight Profile
Fluoxetine demonstrates weight loss of -1.3 kg during acute treatment (4-12 weeks) and weight neutrality in the maintenance phase (>4 months) 1. This represents a significant advantage over both amitriptyline and mirtazapine for long-term metabolic health.
Tolerability
The 2008 ACP guideline found that second-generation antidepressants including fluoxetine had similar adverse effects to each other, with the most common being constipation, diarrhea, dizziness, headache, insomnia, nausea, and sexual side effects 8. However, fluoxetine specifically had:
- Lower sexual dysfunction rates than paroxetine 8
- No significant cardiovascular risks identified 8
- Similar efficacy to other SSRIs with better weight profile 1
Long-Term Safety
While SSRIs as a class show increased risk for nonfatal suicide attempts (OR 1.57), there is no evidence of increased completed suicide risk (OR 0.85) 8. The 2008 guideline found "no differences among second-generation antidepressants" for suicidality risk 8.
Critical Clinical Considerations
Quality of Life Impact
Weight gain with amitriptyline and mirtazapine has "deleterious health consequences" including:
- Impaired patient compliance 1
- Increased cardiovascular risk
- Metabolic syndrome development
- Type 2 diabetes risk 1
Elderly Populations
In older adults, amitriptyline's anticholinergic effects pose particular risks for confusion and cognitive impairment. The 2024 Danish study specifically demonstrated that mirtazapine had worse outcomes in elderly patients, with increased mortality risk 6.
Duration of Treatment Matters
The Endocrine Society emphasizes that "expected length of treatment" must be considered when selecting antidepressants 1. For long-term maintenance therapy, the cumulative burden of weight gain and metabolic effects becomes increasingly significant.
Common Pitfall
Do not assume all second-generation antidepressants have equivalent long-term safety profiles. While acute efficacy may be similar 8, the long-term metabolic, cardiovascular, and tolerability differences are substantial and clinically meaningful 1, 6.